MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Lowers Holdings in Eli Lilly and Company $LLY

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH reduced its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,841 shares of the company's stock after selling 10,723 shares during the period. Eli Lilly and Company makes up 1.5% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's portfolio, making the stock its 27th biggest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's holdings in Eli Lilly and Company were worth $52,105,000 at the end of the most recent quarter.Get Eli Lilly and Company alerts:Eli Lilly’s Oral GLP-1 Breakthrough Could Change EverythingSeveral other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Prostatis Group LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $275,000. Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $43,000. Finally, Fire Capital Management LLC purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $1,028,000. Institutional investors own 82.53% of the company's stock. Eli Lilly and Company Stock Down 3.8%LLY opened at $713.87 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business's 50-day moving average price is $735.09 and its 200-day moving average price is $767.88. The company has a market cap of $675.65 billion, a P/E ratio of 46.66, a P/E/G ratio of 1.03 and a beta of 0.47. Vanguard’s VUG ETF: The Ultimate Growth ETF for Your PortfolioEli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year. Analyst Upgrades and DowngradesA number of research firms have commented on LLY. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a research note on Sunday, August 17th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Berenberg Bank restated a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Guggenheim dropped their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $939.61.As the Market Rotates, This Healthcare ETF Is Leading the WayGet Our Latest Analysis on LLYInsider Transactions at Eli Lilly and CompanyIn other news, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders. About Eli Lilly and Company (Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.Read MoreFive stocks we like better than Eli Lilly and CompanyWhy Are Stock Sectors Important to Successful Investing?Lower Rates Put RV Stocks Back in the Fast LaneInsider Buying Explained: What Investors Need to KnowAlphabet: Time to Take Profits, Buy, or Wait for a Pullback?Canadian Penny Stocks: Can They Make You Rich? Hershey vs. Mondelez: Which Stock Wins Chocolate Season?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eli Lilly and Company Right Now?Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here